Nordic Nanovector ASA signs second ADC deal in a month

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Cancer, Protein

Nordic Nanovector ASA and Heidelberg Pharma GmbH will develop antibody drug conjugate (ADC) treatments for leukaemias under a deal agreed this week.

CFO, Tone Kvåle, told us Nordic will contribute “the antibody targeting a specific antigen on the surface of leukaemia cells and expertise in its chemistry and manufacture, as well as development expertise for targeted therapeutics should a suitable candidate ADC be developed.

"Heidelberg Pharma (HP) brings its complementary technologies for creating ADCs through conjugation of tumour cell killing payloads to tumour targeting antibodies​," he added, explaining that these capabilities were the primary motivation for the deal.

Kvåle declined to share details of either the antibody or the small molecule payload to which it will be attached.

Strategic plan

The deal is part of Nordic’s wider strategic effort to expand its business beyond its core portfolio of radionuclide-based cancer medications.

The Norway-based drug firm recently signed another ADC-focused agreement, partnering with South Korean firm LegoChem. The agreement will also focus on the development of ADC treatments for leukaemias.

Kvåle told us “diversification of the portfolio is a strategic aim for NN, whereby its expertise is leveraged alongside complementary expertise from partners to create new targeted therapies for haematological cancers.

He cited both the ADC deal withLegoChem and Nordic’s antibody radionuclide conjugate (ARC) focused agreements withthe Paul Scherrer Institute and Areva Med as examples.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more